SuperworthHaemonetics EPS HAE
Diluted earnings per share by quarter and over the last twelve months, from 2009.
- Last 12 months, to Jun 27, 2026
- $2.04
- Latest quarter, Q1 FY27
- $0.72
- +3% on a year earlier
- Fiscal year 2026
- $2.02
- −39% on the year before
Haemonetics' earnings per share was $2.04 over the twelve months to Jun 27, 2026, down 38% on a year earlier.
In its latest quarter, Q1 FY27, it was $0.72, up 3% on the same quarter a year before.
Over the five fiscal years to FY2026 it grew 5% a year on average.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2026 | $2.02 | −39% |
| FY2025 | $3.31 | +45% |
| FY2024 | $2.29 | +3% |
| FY2023 | $2.23 | +165% |
| FY2022 | $0.84 | −46% |
| FY2021 | $1.55 | +5% |
| FY2020 | $1.47 | +40% |
| FY2019 | $1.05 | +22% |
| FY2018 | $0.86 | n/a |
| FY2017 | −$0.50 | n/a |
| FY2016 | −$1.10 | −444% |
| FY2015 | $0.32 | −52% |
| FY2014 | $0.67 | −11% |
| FY2013 | $0.75 | −42% |
| FY2012 | $1.30 | −17% |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q1 FY27 | $0.72 | +3% | $2.04 | |
| Q4 FY26 | −$0.44 | −138% | $2.02 | |
| Q3 FY26 | $0.95 | +28% | $3.63 | |
| Q2 FY26 | $0.81 | +23% | $3.42 | |
| Q1 FY26 | $0.70 | −5% | $3.27 | |
| Q4 FY25 | $1.17 | +193% | $3.31 | |
| Q3 FY25 | $0.74 | +21% | $2.54 | |
| Q2 FY25 | $0.66 | +38% | $2.41 | |
| Q1 FY25 | $0.74 | −8% | $2.23 | |
| Q4 FY24 | $0.40 | −30% | $2.29 | |
| Q3 FY24 | $0.61 | −5% | $2.46 | |
| Q2 FY24 | $0.48 | −25% | $2.49 |
Against its peers
Companies in Medical - Instruments & Supplies nearest Haemonetics' size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| HAEHaemonetics | $2.04 | −38% a year |
| MMSIMerit Medical Systems | $2.42 | +23% a year |
| VNTVontier | $2.41 | −8% a year |
| BMIBadger Meter | $4.28 | −8% a year |
| ICUIICU Medical | $1.18 | |
| MSAMSA Safety | $8.04 | +15% a year |
| NVSTEnvista | $0.58 | +81% a year |
| WRBYWarby Parker | $0.07 | |
| ATRCAtriCure | $0.21 | |
| PODDInsulet | $5.35 | +64% a year |
| GMEDGlobus Medical | $3.91 | +50% a year |
| Peer median | $2.42 |
Where Haemonetics ranks
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Haemonetics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.